

# HEALTHY U CHIP

## PRIOR AUTHORIZATION REQUEST FORM

### HYPERKALEMIA

Lokelma<sup>®</sup>, Veltassa<sup>®</sup>

**For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U CHIP Prior Authorization Department at 385-425-4052.**

**Failure to submit clinical documentation to support this request will result in a dismissal of the request.**

If you have prior authorization questions, please call for assistance: 385-425-5094

Disclaimer: Prior Authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:		

**Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.**

**Preferred:**  Veltassa<sup>®</sup> (patiomer)

**Non-Preferred:**  Lokelma<sup>®</sup> (sodium zirconium cyclosilicate)

Dosing/Frequency: \_\_\_\_\_

#### If the request is for reauthorization, proceed to reauthorization section

Questions	Yes	No	Comments/Notes
1. Is the request for Hyperkalemia?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Is the member between the ages of 18-80?	<input type="checkbox"/>	<input type="checkbox"/>	
3. Is the request from, or in consultation with, a nephrologist or a cardiologist, or is the member pending hospital discharge?	<input type="checkbox"/>	<input type="checkbox"/>	
4. Does the member have a serum potassium level between 5.5-6.5 mmol/L on two separate screenings?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please Provide Documentation</b>
5. If applicable, has the member tried dietary consultations to limit potassium intake?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please Provide Documentation</b>
6. If applicable, has the member tried discontinuing non-steroidal anti-inflammatories?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please Provide Documentation</b>
7. If applicable, has the member tried discontinuing potassium supplements?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please Provide Documentation</b>
8. If applicable, has the member tried reducing or discontinuing angiotensin enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), or renin-angiotensin-aldosterone system (RAAS) inhibitors?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please Provide Documentation</b>
9. Has the member had a trial and failure of a loop or thiazide diuretic (excluding potassium-sparing diuretics)?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please Provide Documentation</b>
10. Is the requested medication being used to bridge a member with stage 5 kidney dysfunction to dialysis?	<input type="checkbox"/>	<input type="checkbox"/>	

REAUTHORIZATION			
1. Is the request for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Does updated clinical documentation show that the member's serum potassium is <5.5 mmol/L secondary to the use of patiromer (Veltassa)?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please Provide Documentation</b>
<b>What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.</b>			
Additional information:			
Physician's Signature:			

**\*\*Failure to submit clinical documentation to support this request will result in a dismissal of the request.\*\***

Policy: PHARM-CHIP-033  
 Origination Date: 07/01/2024  
 Reviewed/Revised Date:  
 Next Review Date:  
 Current Effective Date: 07/01/2024

**Confidentiality Notice**

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.